Schlessinger J: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002, 110: 669-672. 10.1016/S0092-8674(02)00966-2.
Article
CAS
PubMed
Google Scholar
Atalay G, Cardoso F, Awada A, Piccart MJ: Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol. 2003, 14: 1346-1363. 10.1093/annonc/mdg365.
Article
CAS
PubMed
Google Scholar
Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992, 13: 3-17. 10.1210/er.13.1.3.
CAS
PubMed
Google Scholar
Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S: Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 2002, 71: 67-75. 10.1023/A:1013397232011.
Article
PubMed
Google Scholar
Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003, 200: 290-297. 10.1002/path.1370.
Article
CAS
PubMed
Google Scholar
Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995, 55: 5536-5539.
CAS
PubMed
Google Scholar
Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ: Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell. 1990, 61: 1147-1155. 10.1016/0092-8674(90)90077-R.
Article
CAS
PubMed
Google Scholar
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182.
Article
CAS
PubMed
Google Scholar
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17: 2639-2648.
Article
CAS
PubMed
Google Scholar
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.
Article
CAS
PubMed
Google Scholar
Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithms. J Clin Oncol. 2003, 21: 2889-2895. 10.1200/JCO.2003.02.018.
Article
CAS
PubMed
Google Scholar
Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW, et al: C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 1996, 74: 229-233.
Article
CAS
PubMed
PubMed Central
Google Scholar
Soltoff SP, Carraway KLIII, Prigent SA, Gullick WG, Cantley LC: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994, 14: 3550-3558.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, et al: HER4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cell. Mol Cell Biol. 2001, 21: 4265-4275. 10.1128/MCB.21.13.4265-4275.2001.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG: Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labeling. Breast Cancer Res. 2004, 6: R246-R251. 10.1186/bcr783.
Article
CAS
PubMed
PubMed Central
Google Scholar
Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol. 2002, Suppl 11: 11-21. 10.1053/sonc.2002.34049.
Article
Google Scholar
Xia W, Liu L-H, Ho P, Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 2004, 23: 646-653. 10.1038/sj.onc.1207166.
Article
CAS
PubMed
Google Scholar
Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003, 8: 303-306.
Article
CAS
PubMed
Google Scholar
Albain K, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S, Rubi S: Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer [abstract 20]. Breast Cancer Res Treat. 2002, 76 (Suppl 1): s33-
Google Scholar
Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L, Gee J, Nicholson RI: Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study [abstract 23]. Proc Am Soc Clin Oncol. 2003, 22: 7-
Google Scholar
Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Gonzalez S, Guillen V, Sauleda S, Averbuch S, Rojo F: Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer [abstract 24]. Proc Am Soc Clin Oncol. 2003, 22: 7-
Google Scholar
Winer E, Cobleigh M, Dickler M, Miller K, Fehrenbacher L, Jones C, Justice R: Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer [abstract 445]. Breast Cancer Res Treat. 2002, 76 (Suppl 1): s115-
Google Scholar
Tan AR, Yang X, Berman A, Lepper ER, Cox MC, Parr AL, Hewitt SM, Steinberg SM, Lipkowitz S, Swain SM: Evaluation of epidermal growth factor receptor signaling in tumor and skin biopsies after treatment with OSI-774 in patients with metastatic breast cancer [abstract 784]. Proc Am Soc Clin Oncol. 2003, 22: 196-
Google Scholar
Hidalgo M, Erlichman C, Rowinsky EK, Koepp-Norris J, Jensen K, Boni J, Korth-Bradley J, Quinn S, Zacharchuk C: Phase I trial of EKB0569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors [abstract 65]. Proc Am Soc Clin Oncol. 2002, 21: 17a-
Google Scholar
Dees EC, Burris H, Hurwitz H, Dowlati A, Smith D, Koch K, Stead A, Mangum S, Harris J, Spector N: Clinical summary of 67 heavily pre-treated patients with metastatic breast carcinomas treated with GW572016 in a phase Ib study [abstract 3188]. Proc Am Soc Clin Oncol. 2004, 23: 241-
Google Scholar
Murren JR, Papadimitrakopoulou VA, Sizer KC, Vaidyanathan S, Ravera C, Abbruzzese JL: A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers [abstract 377]. Proc Am Soc Clin Oncol. 2002, 21: 95a-
Google Scholar
Blackwell KL, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Sorensen MJ, Berger MS: A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer [abstract 3006]. Proc Am Soc Clin Oncol. 2004, 23: 196-
Google Scholar
Nemunaitis JJ, Eiseman I, Cunningham C, Lenehan P, Olson S, Bycott P, Schlict M, Zentgraff R, Shin D, Zinner R: A phase I trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors [abstract 974]. Proc Am Soc Clin Oncol. 2003, 22: 243-
Google Scholar
Zinner RG, Donato NJ, Nemunaitis JJ, Cunningham CC, Shin HJ, Zentgraf RE, Ayers GD, Glisson BS, Khuri FR, Kies MS, et al: Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor, CI-1033 [abstract 58]. Proc Am Soc Clin Oncol. 2002, 21: 15a-
Google Scholar
Garrison MA, Tolcher A, McCreery H, Rowinsky EK, Schott A, Mace J, Drengler R, Patnaik A, Denis L, Lenehan P, et al: A phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors [abstract 283]. Proc Am Soc Clin Oncol. 2001, 20: a283-10.1023/A:1011817205673.
Google Scholar
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: correlation with clinical response to gefi-tinib therapy. Science. 2004, 304: 1497-1500. 10.1126/science.1099314.
Article
CAS
PubMed
Google Scholar
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139. 10.1056/NEJMoa040938.
Article
CAS
PubMed
Google Scholar
Bacus SS, Beresford PJ, Yarden Y, Spector N, Smith B: The use of predicting factors and surrogate markers in patients' cancer biopsies treated with targeted antibodies to erbB receptors and erbB tyrosine kinase inhibitors [abstract 3408]. Proc Am Soc Clin Oncol. 2003, 22: 848-
Google Scholar
Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003, 21: 2787-2799. 10.1200/JCO.2003.01.504.
Article
CAS
PubMed
Google Scholar
Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004, 22: 1201-1208. 10.1200/JCO.2004.10.182.
Article
CAS
PubMed
Google Scholar
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Van Cutsem E: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [abstract 1012]. Proc Am Soc Clin Oncol. 2003, 22: 252-
Google Scholar
Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M: Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res. 2003, 9: 524S-532S.
CAS
PubMed
Google Scholar
Massarweh S, Shou J, Mohsin SK: Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 ('Iressa') restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors [abstract 130]. Proc Am Soc Clin Oncol. 2002, 21: 33a-
Google Scholar
May BBY, Bristow RB, Kim J, Siu LL: Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol. 2003, 21: 2760-2776. 10.1200/JCO.2003.10.044.
Article
Google Scholar
Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, et al: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003, 17: 1825-1833.
Article
Google Scholar
Bundred NJ, Anderson EA, Gee J, Barr L, Baildam A, Zeiton A, Byrne G, Grassby S, Nicholson RI, Koehler M: Randomised, double-blind, placebo-controlled trial of short-term effects of gefitinib ('Iressa', ZD1839) on ductal carcinoma in situ [abstract 14]. Breast Cancer Res Treat. 2003, 82: s10-
Google Scholar